Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
30 Enero 2024 - 3:01PM
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases, today announced that
it has commenced an underwritten public offering of its common
stock and pre-funded warrants. All shares of common stock and
pre-funded warrants to be sold in the offering will be offered by
Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option
to purchase up to an additional 15% of the number of shares of its
common stock offered in the public offering (including shares
underlying the pre-funded warrants). The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
BofA Securities, Jefferies, Leerink Partners, Evercore ISI,
Guggenheim Securities and Cantor are acting as joint book-running
managers for the offering. BTIG and Needham & Company are
acting as lead managers for the offering.
A shelf registration statement relating to the offered
securities was filed with the Securities and Exchange Commission
(SEC), and was automatically effective upon filing on July 2, 2021.
A preliminary prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and will be
available on the SEC’s website, located at www.sec.gov. Copies
of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may be obtained, when
available, from BofA Securities NC1-022-02-25, Attention:
Prospectus Department, 201 North Tryon Street, Charlotte, North
Carolina 28255-0001 or by email
at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention:
Equity Syndicate Department, 520 Madison Avenue, New York, New York
10022, by telephone at 1-877-821-7388, or by email
at Prospectus_Department@Jefferies.com; Leerink Partners LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, by email at syndicate@leerink.com or by
phone at (800) 808-7525, ext. 6105; and Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, New York 10055, by telephone at 1-888-474-0200 or by
email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About VaxcyteVaxcyte is a vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases. The Company is
developing broad-spectrum conjugate and novel protein vaccines to
prevent or treat bacterial infectious diseases. Vaxcyte’s lead
candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum,
carrier-sparing pneumococcal conjugate vaccine (PCV) being
developed for the prevention of invasive pneumococcal disease and
is proceeding to Phase 3. VAX-31, the Company’s next-generation
31-valent PCV, is the broadest-spectrum PCV candidate in the clinic
today.
Vaxcyte is re-engineering the way highly complex vaccines are
made through modern synthetic techniques, including advanced
chemistry and the XpressCF™ cell-free protein synthesis platform,
exclusively licensed from Sutro Biopharma, Inc. Unlike conventional
cell-based approaches, the Company’s system for producing
difficult-to-make proteins and antigens is intended to accelerate
its ability to efficiently create and deliver high-fidelity
vaccines with enhanced immunological benefits. Vaxcyte’s pipeline
also includes VAX-A1, a prophylactic vaccine candidate designed to
prevent Group A Strep infections; VAX-PG, a therapeutic vaccine
candidate designed to slow or stop the progression of periodontal
disease; and VAX-GI, a vaccine program designed to prevent
Shigella. Vaxcyte is driven to eradicate or treat invasive
bacterial infections, which have serious and costly health
consequences when left unchecked.
Contacts:Janet Graesser, Vice President,
Corporate Communications and Investor RelationsVaxcyte,
Inc.917-685-8799media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor RelationsVaxcyte,
Inc.860-729-8902investors@vaxcyte.com
Vaxcyte (NASDAQ:PCVX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Vaxcyte (NASDAQ:PCVX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024